PeptidesInfo

Research area

Recovery and tissue repair

Recovery is the most-marketed and least-proven area of peptide research. Almost every widely cited healing result comes from rodent models. Human data are limited to small studies, mostly of wound care, and none of the popular injectable 'healing peptides' has an FDA-approved indication.

Abstract illustration of a peptide chain used as the recovery and tissue repair research hub image

Evidence map: peptides studied in this area

How grades work →
PeptideEvidence for this areaRegulatory statusWhat has been studied
Collagen peptidesPromising evidenceNot FDA-approvedSeveral randomised trials report modest improvements in activity-related joint discomfort and some support for tendon/ligament adaptation with training; effect sizes are small and many trials are industry-funded.
GHK-CuPreliminary evidenceNot FDA-approvedCopper peptide complexes have small human wound-healing and skin studies, most decades old, many industry-supported, with mixed quality.
BPC-157Preclinical evidenceNot FDA-approvedExtensive rat studies of tendon, muscle, ligament and gut injury; only one small published human safety/pharmacokinetic dataset and case reports. No controlled efficacy trial in humans.
TB-500Preclinical evidenceNot FDA-approvedThymosin beta-4 has animal wound-healing and cardiac-repair data plus early-phase human trials in dermal wounds and eye conditions; TB-500 as sold is a fragment and has essentially no human trial data.

Grades reflect the strength of evidence for this research area specifically. Definitions: Established, Promising, Preliminary, Preclinical, Unsupported, Conflicting.

What "recovery" research actually measures

Studies in this area rarely measure what athletes and patients care about — time to return to sport, pain-free function, re-injury rate. Instead most measure surrogates: tensile strength of a rat tendon, histological collagen organisation, gene expression in cultured cells, or wound-area reduction in an animal model. Those endpoints matter for understanding mechanism, but they do not tell you whether a person heals faster.

When you read a claim that a peptide "accelerates healing", ask three questions:

  1. Which species? For BPC-157 and TB-500 the answer is almost always rats or mice.
  2. Which injury model? Surgically transected tendons in a young, healthy animal behave differently from an overuse tendinopathy in a 45-year-old human.
  3. Compared with what? Many animal studies compare against saline; almost none compare against standard rehabilitation.

Where the human evidence sits

  • Collagen peptides have the most human trials of anything on this page. Several randomised, placebo-controlled studies in athletes and older adults report modest reductions in activity-related joint pain and small improvements in some tendon and body-composition measures when combined with training. Effects are small and many studies are funded by ingredient manufacturers, but they exist and are reproducible enough for a promising grade.
  • Copper peptides (GHK-Cu) have small human wound-healing and skin trials, most from the 1990s and 2000s. Quality is mixed and much of it is industry-supported; grade preliminary.
  • BPC-157 has decades of animal work from a small number of laboratories and, until recently, no controlled human data at all. That is why it stays preclinical despite its popularity.
  • TB-500 as sold online is a fragment marketed as thymosin beta-4. The full peptide has entered early human trials for dermal wounds and eye conditions; the fragment has essentially none. Grade preclinical.

What would change the grades

A single well-run randomised trial in humans with a functional endpoint would move BPC-157 or TB-500 to preliminary or promising. As of our last update, none is registered with posted results on ClinicalTrials.gov. We re-check quarterly.

Analyses in recovery and tissue repair

Benefits4 min read

Are Peptides Worth It? A Framework for Deciding

Whether a peptide is worth it depends on four things: what benefit is proven, in whom, for how long, and whether the effect lasts after you stop. Here is that framework applied to every peptide we cover.

Benefits5 min read

Peptides for Recovery: Which Benefits Are Actually Documented

Recovery is the most-marketed peptide benefit and the least proven. This separates the recovery claims with human trials behind them from the ones resting entirely on rodent studies — and names what would change the verdict.

Benefits8 min read

Peptide Benefits: What the Evidence Actually Supports

Peptides are credited with dozens of benefits. Some are proven in large trials, some are modest and real, and some have never been tested in a person. This is every major benefit claim, sorted by how strong the human evidence is.

Benefits4 min read

Collagen Peptide Benefits: What to Expect, and When

Collagen peptides have more randomised human trials than any other supplement peptide. The benefits are real, small, and take 8–24 weeks to appear. Here is what each one is worth in measurable terms.

Research analysis6 min read

BPC-157: Human Evidence, Animal Research, and Open Questions

BPC-157 has hundreds of positive animal studies and almost no controlled human data. We separate what the rat research shows, what the few human reports show, what the FDA has said, and what would have to happen for the evidence grade to change.

Research analysis4 min read

TB-500 and Thymosin Beta-4: What the Research Actually Studies

TB-500 is sold on the back of thymosin beta-4 research — a different molecule with real but early human trials in wounds and eye disease. We untangle which studies are about what, and what that means for the fragment people actually buy.

Research analysis4 min read

GHK-Cu: Skin, Hair, Wound Healing, and Evidence Quality

Copper peptide GHK-Cu has decades of laboratory work, small human trials for topical skin use, and a growing injectable market with no human data. We grade each claim — skin, hair, wounds, 'gene resetting' — separately.

Research analysis4 min read

Collagen Peptides: Joint, Skin, and Recovery Evidence

Oral collagen peptides are the rare non-drug peptide product with multiple randomised trials. The effects on skin hydration, activity-related joint pain and (with training) lean mass are real but small, and most trials are industry-funded. Here is what the studies show and where the gaps are.